Beacon 2024 Product Milestones, and a look ahead to 2025.

Immune Tolerance Deals and Companies Dataset.

In February, Beacon Immune Tolerance saw the rollout of its Deals and Companies dataset—adding critical business development intelligence to its already robust scientific data. This addition supports users in sourcing strategic partnerships, benchmarking deal structures, and conducting due diligence on potential collaborators. Whether identifying M&A targets, monitoring the competitive landscape, or evaluating commercial potential, this dataset equips our clients with insights needed to guide informed, strategic decisions​.

Global Trial Locations

In August, Beacon enhanced all datasets with the introduction of Clinical Trial Location Data. This update helps users make strategic decisions around patient recruitment and competitor analysis. By visualizing where trials are being conducted globally, users can identify underutilised regions for recruitment and gain intelligence into the geographic spread of competitor activity, both at a local and global level​.

Beacon Oncology Launch

September marked the launch of Beacon Oncology, our most ambitious dataset to date. Developed from a disease-specific lens this module now provides access to more than 25,000 oncology drugs and 50,000 trials, surpassing competing databases by at least 20% in volume, while maintaining over 95% data accuracy.

Due to its in-depth suite of search filters, Beacon Oncology allows users to investigate drugs and trials across oncology subtypes and modalities, from preclinical to late-stage development. This integrated perspective enables faster decision-making in an increasingly complex oncology landscape and paves the way for additional disease-focused Beacon modules in the future​.

Expanding into Atopic Dermatitis

In October, Beacon expanded its Immune Tolerance dataset with a comprehensive new focus on Atopic Dermatitis (AD). This enhancement includes over 590 drugs and more than 800 clinical trials, with a significant portion already in the clinic. The update also brings coverage of cutting-edge innovations such as JAK inhibitors and IL-13 targeting biologics. The depth and focus of the dataset—alongside curated, immune-specific ontologies—make it a powerful tool for researchers navigating the fast-evolving AD space​.

Oncology Trial Locations and Milestones

By December, Beacon Oncology users gained access to new Trial Location and Milestones data, allowing for deeper visibility into site selection and trial progress. With the Milestones filter and new visualizations, users can now track key clinical and regulatory readouts, identify trial locations, and map drug development timelines with greater clarity. These additions support more efficient competitive intelligence gathering and better-informed trial planning strategies​.

Looking Ahead to 2025

Beacon is building on its 2024 successes with significant plans for 2025:

• UX/UI Upgrade: A redesigned user interface will streamline the research journey. A new homepage, enhanced result lists, and personalized content will make it easier than ever to find and act on the most relevant data.
• API Integration: The upcoming launch of APIs will allow users to pull Beacon data directly into internal systems—empowering scientific, commercial, and strategic teams with seamless, real-time intelligence.
• Beacon Oncology: Deals and Companies: In early 2025, our clients will be able to access company profiles and deal activity within Beacon Oncology, offering greater visibility into commercial strategy and partnership landscapes.
• Patent Dataset Launch: A new patent search tool will allow users to understand intellectual property trends, strengthening strategic planning in discovery and development.

We believe that these enhancements will further Beacon’s mission to become the intelligence partner of choice for the pharmaceutical and biotech industry, with data tools that support every step of the drug development process.